Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer
Not Applicable
Completed
- Conditions
- Neoplasms
- Registration Number
- KCT0009052
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Compatible with borderline resectable or locally advanced pancreatic cancer based on NCCN
- Administered neoadjuvant chemotherapy before surgery
- Available data of positive emission tomographym and carbohydrate antigen 19-9 during neoadjuvant chemotherapy
Exclusion Criteria
- The patients with distant metastasis
- The patients who underwent upfront surgery without neoadjuvant chemotherapy
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method recurrence free survival